In agreement, upon response to anti-TNF-α therapy intestinal CD4+ T-cells isolated from IBD patients exhibit reduced amounts of IL-22BP expression but still express IL-22 [212], and may even up-regulate IL-22 production [215]. This evidence concerns the gene IL22 and inflammatory bowel disease.